These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Resolution of cystic fibrosis-related diabetes with ivacaftor therapy. Hayes D; McCoy KS; Sheikh SI Am J Respir Crit Care Med; 2014 Sep; 190(5):590-1. PubMed ID: 25171312 [No Abstract] [Full Text] [Related]
9. [Combined administration of lumacaftor and ivacaftor as a causal therapeutic approach]. Desch M Med Monatsschr Pharm; 2016 Jan; 39(1):42-4. PubMed ID: 26975180 [No Abstract] [Full Text] [Related]
10. Improvement of sinus disease in cystic fibrosis with ivacaftor therapy. Hayes D; McCoy KS; Sheikh SI Am J Respir Crit Care Med; 2014 Aug; 190(4):468. PubMed ID: 25127305 [No Abstract] [Full Text] [Related]
11. Lumacaftor/ivacaftor (Orkambi) for cystic fibrosis. Med Lett Drugs Ther; 2016 Mar; 58(1491):41-2. PubMed ID: 27027688 [No Abstract] [Full Text] [Related]
12. Foundation receives $3.3-billion windfall for Kalydeco. Senior M Nat Biotechnol; 2015 Jan; 33(1):8-9. PubMed ID: 25574617 [No Abstract] [Full Text] [Related]
13. A young Hispanic with c.1646G>A mutation exhibits severe cystic fibrosis lung disease: is ivacaftor an option for therapy? Yarlagadda S; Zhang W; Penmatsa H; Ren A; Arora K; Naren AP; Khan FA; Donnellan CA; Srinivasan S; Stokes DC; Kappes JC Am J Respir Crit Care Med; 2012 Oct; 186(7):694-6. PubMed ID: 23027855 [No Abstract] [Full Text] [Related]
14. CT imaging of pediatric patients with cystic fibrosis on ivacaftor therapy. Hayes D; Long FR; McCoy KS; Sheikh SI Lung; 2014 Oct; 192(5):823-4. PubMed ID: 25099273 [No Abstract] [Full Text] [Related]
15. Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. Ratjen F; Klingel M; Black P; Powers MR; Grasemann H; Solomon M; Sagel SD; Donaldson SH; Rowe SM; Rosenfeld M Am J Respir Crit Care Med; 2018 Aug; 198(4):526-528. PubMed ID: 29614238 [No Abstract] [Full Text] [Related]
16. Immeasurable Time Bias In Exposure to Ivacaftor. Sarayani A; Winterstein AG Health Aff (Millwood); 2019 Feb; 38(2):328. PubMed ID: 30715971 [No Abstract] [Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment. Pettit RS Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718 [TBL] [Abstract][Full Text] [Related]
19. Ivacaftor, vismodegib, and ingenol mebutate. Hussar DA; Eckel SP J Am Pharm Assoc (2003); 2012; 52(3):418-22. PubMed ID: 22618984 [No Abstract] [Full Text] [Related]
20. Sweat chloride is not a useful marker of clinical response to Ivacaftor. Barry PJ; Jones AM; Webb AK; Horsley AR Thorax; 2014 Jun; 69(6):586-7. PubMed ID: 24258833 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]